Clinical Trial Update: A Clinical Trial on the Antipsychotic Properties of Cannabidiol [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 clinical trial evaluating the antipsychotic properties of cannabidiol in schizophrenia and other psychotic dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorders
• Schizophrenia

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: University of Cologne | Conditions: Schizophrenia, Psychotic Disorders | Phase 2 | Status: COMPLETED